Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NCCN task force report: molecular markers in leukemias and lymphomas.

Journal of the National Comprehensive Cancer Network : JNCCN - 1 Jul 2009

Radich Jerald P, Zelenetz Andrew D, Chan Wing C, Croce Carlo M, Czuczman Myron S, Erba Harry P, Horning Sandra J, Houldsworth Jane, Smith B Douglas, Snyder David S, Sundar Hema M, Wetzler Meir, Winter Jane N

Abstract excerpt

The introduction of targeted therapies has revolutionized treatment and improved outcomes in patients with leukemias and lymphomas. However, many patients experience relapse caused by the persistence of residual malignant cells. Cytogenetic and molecular techniques are increasingly being used to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Fusion
Share to Immunophenotyping

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Leukemia, Myeloid, Acute

Share to Lymphoma, Non-Hodgkin

Share to MicroRNAs

Share to Neoplasm, Residual

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Source

Identifiers

PMID: 19635230
DOI: 10.6004/jnccn.2009.0077

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19635230-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NCCN task force report: molecular markers in leukemias and lymphomas.PMID 19635230Read ↗

Minimal Residual Disease Detection in Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions.Semantic proximity Read ↗

Predictive and prognostic molecular biomarkers in lymphomas.Semantic proximity Read ↗

An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemiaSemantic proximity Read ↗

Emerging molecular predictive and prognostic factors in acute myeloid leukemia.Semantic proximity Read ↗

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.Semantic proximity Read ↗

Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician.Semantic proximity Read ↗

Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markersSemantic proximity Read ↗

Molecular Diagnosis of the Hematologic CancersSemantic proximity Read ↗

Molecular Monitoring of Lymphomas.Semantic proximity Read ↗

Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemiaSemantic proximity Read ↗

Novel Tools for Diagnosis and Monitoring of AML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.